Success fee to Bioinvent and partner
The cancer collaboration started last year. After successful technology transfer the two partner companies now receives 5 million euro from pharma giant Roche.
Bioinvent and Thrombogenics entered the strategic alliance with Roche in June 2008, when Roche paid EUR 50 million upfront to Bioinvent and Thrombogenics. The whole deal has a potential worth of up to EUR 450 million, depending on a series of pre-defined development and commercial milestones, plus the chance of future double digit royalties. Thrombogenics discovered the compound, and thus earns 60 per cent of the net.
The clinical program is now in Phase Ib. According to the agreement, Roche covers all development costs, including the clinical studies currently run by Bioinvent and Thrombogenics.
